Anaptysbio (ANAB) Preferred Stock Liabilities (2016)

Anaptysbio (ANAB) posted Preferred Stock Liabilities of $28.2 million for Q4 2016.

Anaptysbio (ANAB) Preferred Stock Liabilities (2016) Analysis & Trends

Anaptysbio's Preferred Stock Liabilities history runs 1 years deep, the most recent figure standing at $28.2 million for Q4 2016.

Quarterly Preferred Stock Liabilities changed N/A year-over-year to $28.2 million in Q4 2016, while the trailing twelve-month figure through Dec 2016 was $28.2 million (changed N/A YoY) and the FY2016 annual result came in at $28.2 million, changed N/A from the prior year.
Preferred Stock Liabilities was $28.2 million for Q4 2016 at Anaptysbio.
Across five years, Preferred Stock Liabilities topped out at $28.2 million in Q4 2016 and bottomed at $28.2 million in Q4 2016.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Preferred Stock Liabilities (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	-
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	-
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Anaptysbio	1.58 Bn	1.29 Bn	-	-

Download Data

Date	Value
Dec 31, 2016	28.22 Mn